Soligenix Shares Rise 17% on FDA Clearance
By Dean Seal
Shares of Soligenix Inc. gained 17% to 65 cents in premarket
trading Tuesday after the company said regulators had cleared an
investigational new drug application for a clinical trial examining
its psoriasis treatment.
The company said the Food and Drug Administration had cleared
the application for a Phase 2a trial designed to evaluate SGX302 as
a topically applied treatment for mild to moderate psoriasis.
The trial will be a randomized, double-blind and
placebo-controlled study of up to 32 adults with stable psoriasis
covering between 2% and 30% of their bodies. Treatment will last
for up to 18 weeks, Soligenix said.
Patient enrollment is expected to begin in the fourth quarter of
Write to Dean Seal at firstname.lastname@example.org
(END) Dow Jones Newswires
June 28, 2022 08:12 ET (12:12 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.